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Objective: Differentiated articular chondrocytes express a functional bisoform of the leptin receptor
(LRb); however, leptin-LRb signaling in these cells is poorly understood. We hypothesized that leptin-LRb
signaling in articular chondrocytes functions to modulate canonical Wnt signaling events by altering the
expression of Frizzled (FZD) receptors.
Methods: Human chondrocyte cell lines and primary articular chondrocytes were grown in serum con-
taining growth media for 24 h, followed by a media change to Dulbecco’s modiﬁed Eagle’s medium
(DMEM) containing 1% Nutridoma-SP to obtain a serum-deﬁcient environment for 24 h before treatment.
Treatments included recombinant human leptin (10e100 nM), recombinant human IL-6 (0.3e3 nM), or
recombinant human erythropoietin (Epo) (10 mU/ml). Cells were harvested 30 mine48 h after treatment
and whole cell lysates were analyzed using immunoblots or luciferase assays.
Results: Treatment of cells with leptin resulted in activation of Janus kinase 2 (JAK2) and subsequent
phosphorylation of speciﬁc tyrosine residues on LRb, followed by dose- and time-dependent increases in
the expression of Frizzled-1 (FZD1) and Frizzled-7 (FZD7). Leptin-mediated increases in the expression of
FZD1 were blocked by pre-treatment with the protein synthesis inhibitor cycloheximide or the JAK2
inhibitor AG490. Experiments using a series of hybrid Epo extracellular domain-leptin intracellular
domain receptors (ELR) harboring mutations of speciﬁc tyrosine residues in the cytoplasmic tail showed
that increases in the expression of FZD1 were dependent on LRb-mediated phosphorylation of STAT3, but
not ERK1/2 or STAT5. Leptin pre-treatment of chondrocytes prior to Wnt3a stimulation resulted in an
increased magnitude of canonical Wnt signaling.
Conclusion: These experiments show that leptin-LRb signaling in articular chondrocytes modulates
expression of canonical Wnt signaling receptors and suggests that direct cross-talk between these
pathways is important in determining chondrocyte homeostasis.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Obesity is a major epidemiological risk factor for the develop-
ment of knee osteoarthritis (OA), but molecular links between
obesity and the risk of knee OA are unknown1e6. Over the last few
years several laboratories have established hypothetical links
between the adipokine leptin and development of knee OA7e10.
Recently, it has been reported that leptin is signiﬁcantly elevated in
synovial ﬂuid of patients with OA, providing an additional epide-
miological link to the development of OA7,11.lake J. Roessler, 3560 MSRB2,
88, USA. Tel: 734-763-7949;
.
Surgery, Nagasaki University,
s Research Society International. PLeptin is a 16 kDa protein secreted by white adipose tissue, and
encoded by the obese (ob/ob) gene12. Leptin signals via leptin
receptors (LR),members of the class I cytokine receptor family13 that
include the prototypic interleukin 6 receptor (IL-6R). Six isoforms of
LR have been identiﬁed, but the b isoform (LRb) is responsible for
intracellular signal transduction14,15. LRb associates with Janus
kinase 2 (JAK2) tyrosine kinase to initiate intercellular signaling via
phosphorylation of LR tyrosine residues Tyr985, Tyr1077 and
Tyr1138. Tyr985 and Tyr1138 recruit SH2 domain-containing tyro-
sine phosphatase (SHP-2) and signal transducer and activator of
transcription-3 (STAT3), respectively16. Tyr985/SHP-2 is a major
regulator of downstream extracellular signal-regulated kinase 1/2
(ERK1/2) activation, while Tyr1138/STAT3 induces expression of
several downstream effectors including the negative feedback
regulator SOCS317,18.
Leptin controls energy balance and body weight through LR
signaling in the central nervous system (CNS), and regulatesublished by Elsevier Ltd. All rights reserved.
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collagen synthesis, bone growth and mineralization19e23. However,
it remains unclear whether these effects are mediated via periph-
eral LR signaling events or exclusively by CNS pathways22,23.
Wnts are members of a gene family representing mammalian
orthologs of wingless, a Drosophila patterning gene (including 19
human Wnt genes). Wnt genes encode secreted glycoproteins that
regulate critical aspects of morphogenesis in an extensive array of
tissues24. Wnt-regulated signal transduction involves two well-
described pathways, canonical signaling with activation of
b-catenin and non-canonical signaling with intracellular calcium
release and activation of protein kinase C25. Activation of both
pathways is associated with binding of Wnts to their cognate
receptors, a family known as Frizzled (FZD). In addition, Wnt/b-
catenin signaling regulates expression of cyclo-oxygenase-2 and
several matrix metalloproteinases (MMPs)26e33. MMP-13 has been
shown to degrade arthritis cartilage in human joints34. Both human
genetic data and transgenic mouse studies have linked the Wnt
signaling antagonist soluble FZD-related protein 3 to protection
against OA. Functional parallels between FZD and LRb signaling in
chondrocytes and osteoblasts are worth noting as activation of
either pathway yields signiﬁcant effects on cell differentiation and
composition of extracellular matrix14,15. A previous study showed
that leptin deﬁciency protects animals from liver ﬁbrosis, sug-
gesting that leptin may modulate expression of metalloproteinases
by target cells13. Collectively, these ﬁndings suggest the hypothesis
that a mechanistic link between FZD and LRb signaling pathways
functions in articular chondrocytes.
We show that LR signaling pathways are operative in articular
chondrocytes and identify FZD receptors as downstream target
genes. Although 10 human FZD receptors have been identiﬁed and
characterized, in these initial studies we chose to examine
a subgroup (FZD1, FZD2 and FZD7) that show similar structural
organization at the genomic level and a high degree of shared
amino acid identity (75%)35. We show that leptin stimulation
induces expression of FZD1 and FZD7, but not FZD2. LRb activation
resulted in JAK2, ERK1/2 and STAT3 phosphorylation. To identify
speciﬁc LRb signaling pathways, an Epo-LR (ELR) chimera con-
taining the extracellular domain of Epo receptor and the intracel-
lular domain of leptinwas used, since articular chondrocytes do not
express Epo receptor. Mutation of Tyr1138, but not Tyr985 or
Tyr1077, in the chimeric ELR blocked both STAT3 phosphorylation
and leptin-induced FZD1 expression. We also demonstrate that
leptin-mediated increases in the expression of FZD are associated
with an increased magnitude of canonical Wnt signaling following
exposure to recombinant Wnt3a. These results suggest “cross-talk”
between leptin and Wnt signaling occurs in articular chondrocytes
whereby leptin modulates expression of Wnt receptors through
a JAK2/STAT3-dependent pathway.
Methods
Cell culture and cell stimulation
Human chondrocyte cell lines (C-28/I2 and T/C-28a2; Mary
Goldring, Ph.D., Hospital for Special Surgery), an osteoblast cell line
(hFOB1.19; ATCC), and human primary chondrocytes derived from
cartilage of a 77-year-old female (Asterand, Detroit, MI) were
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) with
25 mM glucose (Invitrogen), 100 units/ml penicillin, 100 mg/ml
streptomycin (Invitrogen), and 10% fetal bovine serum (Invitrogen)
at 37 C in 5% CO2. Cells were seeded onto 10 cm dishes
(5105 cells) for 24 h in complete media, followed by DMEM 1%
Nutridoma-SP (Roche) for 24 h before treatment with human
recombinant leptin (Sigma, 100 nM unless otherwise noted), IL-6(R&D Systems, 3 nM), or recombinant Epo (Amgen, 10 mU/ml).
Where indicated, recombinant Dkk-1 (R&D Systems, 100 ng/ml)
was added contemporaneously with leptin. Recombinant human
Wnt3a (R&D Systems, 100 ng/ml) was added 6 h prior to cell
harvest. Cycloheximide (Sigma, 10 mg/ml), JAK2 phosphorylation
inhibitor Tyrphostin AG490 (LC Laboratories, 50 nM) and phos-
phoinositide 3-kinase (PI3K) inhibitors LY294002 (Calbiochem,
25 mM) and wortmannin (Sigma, 50 nM) were added 30 min before
leptin.
Plasmids and plasmid transfection
Wild-type and tyrosine mutant ELR expression plasmids
(Martin Myers, M.D., Ph.D., University of Michigan) are previously
described16. pLentilox-topﬂash-3xTCF-LUC and pLentilox-reverse
topﬂash-3xTCF-LUC were constructed by removing U6-shRNA and
CMV-GFP expression cassettes from pLentiLox3.7 (Vector Core,
University of Michigan), then inserting a topﬂash-3x TCF-Luciferase
expression cassette (pLentilox-topﬂash-3xTCF-LUC). C-28/I2 and T/
C-28a2 cells were passed 1 day prior to transfection on 10 cm plates
(3105 cells) in complete media. Cells were transfected using 2 mg
of ELR plasmid and 8 mg polyethylenimine (PEI) in 400 ml Optimem I
(no serum) (Invitrogen) for 20 min at room temperature, incubated
an additional 24 h in complete media, and stimulated as described
above.
Lentivirus production and transduction
Lentivirus packaging vectors (pMDL-RRE, pRSV-REV, pC1-VSVG)
were co-transfected with pLentilox-topﬂash-3xTCF-LUC proviral
plasmid into 293 T cells by the University of Michigan Vector Core
using PEI precipitation. Supernatants were collected after 72 h,
pelleted, then resuspended at 10X the original concentration
(w1107 TU/ml). C-28/I2 cells were seeded on a six well plate
(1.5105 cells/well) one day prior to lentiviral infection. Cell media
was changed to 1.2 ml of fresh complete media, then 0.3 ml of 10x
virus and 8 mg Polybrene (Sigma) were added and centrifuged at
2,500 rpm for 30 min at 27 C.
Protein extraction and Western blotting
Cells were rinsed with ice-cold phosphate-buffered saline (PBS)
and harvested in 200 ml RIPA buffer containing Complete, Mini
protease inhibitor cocktail (Roche) and 1X Halt phosphatase
inhibitor cocktail (Pierce). Equal amounts of lysate were subjected
to SDS-PAGE using 10% Ready-Gel polyacrylamide gels (Bio-Rad
Laboratories) and transferred to Immobilon-P membranes (Milli-
pore Corp., Bedford, MA) as described36. Membranes were blocked
in PBS containing 0.1% tween-20 (PBST) plus 5% nonfat dry milk for
1 h before incubation with primary antibody (anti-JAK2, anti-
phosphorylated JAK2 (pJAK2), anti-ERK, anti-phosphorylated ERK3
(pERK3), anti-STAT3, anti-phosphorylated STAT3 (pSTAT3), anti-
Akt, anti-phosphorylated Akt (pAkt), anti-glyceraldehyde 3 phos-
phate dehydrogenase (GAPDH) (Cell Signaling), anti-Bone
Morphogenic Protein Receptor 1A (BMPR-1A, Zymed), anti-FZD1
(R&D), anti-FZD2 (Abcam) and anti-FZD7 (Abcam)) overnight at
4 C. All primary antibodies were diluted 1:1000 except STAT3
(1:2000) and GAPDH (1:4000) in PBST plus 5% nonfat dry milk.
After washing with PBST, membranes were incubated with horse-
radish peroxidase-conjugated donkey anti-rabbit secondary anti-
bodies (Cell Signaling) diluted 1:2000 in PBST plus 5% nonfat dry
milk for 1 hr at room temperature. After washing with PBST,
immunoreactive bands were visualized using chemoluminescence
reagents (Pierce) and exposed to ﬁlm (CL-Xposure Film, Thermo
Scientiﬁc). Probed blots were stripped (25 mM glycine, 1% SDS, pH
Fig. 1. LR signaling induces expression of FZD1 in articular chondrocytes.
Chondrocytes (C-28/I2) were treated with recombinant leptin (100 nM) and harvested
over a time course (0e48 h). Whole cell lysates were separated by SDS-PAGE and
analyzed using antibodies speciﬁc for (A) FZD1, (B) FZD2 and FZD7 protein. Band
intensities (shown as representative photographs) were quantiﬁed using densitometry,
and in each case t¼ 0 was set to 1 r.u. Tables represent means of four or more separate
experiments with 95% conﬁdence intervals represented as (lower limit, upper limit)
and P-values. Signiﬁcant increases in levels of FZD1 and FZD7 protein were observed at
24 and 48 h, but no change in levels of FZD2 was observed. (C) C-28/I2 cells pre-treated
with cycloheximide (10 ng/ml) prior to treatment with recombinant leptin (100 nM)
did not increase levels of FZD1 in response to leptin treatment. Whole cell lysates were
separated by SDS-PAGE and analyzed using antibodies speciﬁc for FZD1. GAPDH
protein levels analyzed as controls remained unchanged in all experiments.
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normalization. Densitometry was calculated using Scion Image
software, and values expressed as meanþ 95% conﬁdence interval
with statistical signiﬁcance determined by Student’s t-test.
Luciferase assay
Cells transduced with Lentivirus-topﬂash-3xTCF-LUC were
cultured as described above. Cells were harvested in 1x Reporter
Lysis Buffer (Promega) and lysates were centrifuged and assayed for
luciferase activity (Luciferase Assay System, Promega) and quanti-
ﬁed (Monolight 3010 luminometer, BD Biosciences). Whole cell
lysates were assayed in triplicate and results expressed as relative
light units (RLU) normalized to milligrams of total protein content
(Bradford Reagent, Bio-Rad). Statistical signiﬁcance was evaluated
by Student’s t-test.
Results
Leptin induces expression of FZD1 and FZD7 in articular
chondrocytes
We examined whether leptin-LRb signaling was a regulator of
Wnt signaling via FZD receptors in human articular chondrocytes
(C-28/I2 and T/C-28a2 cell lines). These cells express type II
collagen, decorin, aggrecan and other proteins associated with
a differentiated articular chondrocyte phenotype, and have been
used extensively as in vitro model systems for studies of chon-
drocyte biology37,38. C-28/I2 cells were treatedwith leptin (100 nM)
and harvested at 0, 6, 12, 24 and 48 h after leptin treatment, and
FZD receptor protein levels determined. Leptin stimulation resulted
in a signiﬁcant increase in FZD1 and FZD7 protein levels as early as
24 h after treatment and a 3-fold increase within 48 h of treatment
[Fig. 1(A) and (B)]. Leptin stimulation had little effect on FZD2
protein levels in the C-28/I2 cells [Fig. 1(B)]. Leptin stimulation of
the T/C-28a2 cell line also showed induction of FZD1 similar to
C-28/I2 cells, but not FZD7 or FZD2 (data not shown) while GAPDH
showed no signiﬁcant change between samples.
To further explore the mechanism of leptin-induced FZD1
increases, we added cycloheximide 30 min prior to leptin treat-
ment [Fig. 1(C)]. As expected, leptin-induced FZD1 expression was
signiﬁcantly blocked in the presence of cycloheximide, while
GAPDH showed no signiﬁcant change in levels before and after
treatment with leptin. These results are consistent with leptin-
induced de novo protein synthesis of FZD1.
Leptin induces JAK2, ERK1/2 and STAT3 phosphorylation in articular
chondrocytes
It has been shown, primarily in theCNS, that leptin binding to LRb
activates JAK2phosphorylation,which, in turn, activates ERK1/2 and
STAT3 signaling cascades. To test whether leptin functions through
a similar signaling cascade in articular chondrocytes, C-28/I2 cells
were treatedwith leptin and analyzed in a time-dependentmanner.
Whole cell extracts were examined for both phosphorylated and
non-phosphorylated JAK2 [Fig. 2(A)]. Leptin treatment caused
increased JAK2 phosphorylationwithin 10 min and increased levels
of phosphorylated JAK2 were observed for approximately 30 min.
Densitometry showed a 1.7- and 1.5-fold increase in JAK2 stimula-
tionat10and30 min, respectively,withnosigniﬁcant change in total
protein pools of JAK2 and GAPDH. Similar results were observed in
articular chondrocyte cell line T/C-28a2 (data not shown).
To further deﬁne speciﬁc aspects of LRb signaling, ERK1/2
phosphorylation levelswere analyzed in a time-dependentmanner.
Leptin signiﬁcantly induced ERK1/2 phosphorylation as early as
Fig. 3. Leptin stimulation induces phosphorylation of STAT3 and expression of
FZD1 and FZD7 in primary articular chondrocytes.
Primary human articular chondrocytes (passage 2) were treated with leptin (100 nM)
and harvested over a time course (0e48 h). Whole cell lysates were separated by SDS-
PAGE and analyzed using antibodies speciﬁc for STAT3, phospho-STAT3, FZD1 and
FZD7. Leptin treatment induces pSTAT3 accumulation at 30 min (A), increases in the
levels of FZD1 (B) and FZD7 (C) at both 24 and 48 h. GAPDH protein levels analyzed as
controls remained unchanged in all experiments.
Fig. 2. Leptin stimulation induces phosphorylation of JAK2, ERK1/2 and STAT3 in
articular chondrocytes.
Chondrocyte cell lines (C-28/I2 and T/C-28a2) were treated with recombinant leptin
(100 nM) and harvested over a time course (0e100 min). (A) C-28/I2 whole cell lysates
were separated by SDS-PAGE and analyzed using antibodies speciﬁc for JAK2 and
pJAK2. (B) T/C-28a2 whole cell lysates were separated by SDS-PAGE and analyzed using
antibodies speciﬁc for ERK1/2 and pERK1/2. (C) C-28/I2 whole cell lysates were
separated by SDS-PAGE and analyzed using antibodies speciﬁc for STAT3 and pSTAT3.
Band intensities (shown as representative photographs) were quantiﬁed using densi-
tometry and in each case t¼ 0 was set to 1 r.u. Tables represent the mean of three or
more separate experiments with 95% conﬁdence intervals represented as (lower limit,
upper limit) and P-values. Leptin treatment led to signiﬁcant increases in pJAK2 at 10
and 30 min, pERK1/2 at 30 and 100 min, and pSTAT3 at 10, 30 and 100 min. GAPDH
protein levels analyzed as controls remained unchanged in all experiments.
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least 100 min [Fig. 2(B)] in T/C-28a2 cells. A maximum 5-fold
stimulation was observed at 30 min. As internal controls, total
protein levels of ERK1/2 and GAPDH remained unchanged between
samples. Unexpectedly, leptin stimulation of ERK1/2 was not
observed in C-28/I2 cells. In order to reconcile the observed differ-
ences between C-28/I2 and T/C-28a2 cell lines, we repeated the
leptin stimulation experiments using primary human chondrocytes.
These studies showed that leptin-LRb signaling did not result in
signiﬁcant time-dependent phosphorylation of ERK1/2 (data not
shown). In summary, these results suggest that leptin-LRbactivation
of ERK1/2 is not likely to be a major downstream signaling pathway
that leads to induced expression of FZD1 in articular chondrocytes.To test whether leptin stimulation activates time-dependent
STAT3 phosphorylation, the C-28/I2 cell line was treated with
increasing concentrations of leptin and examined for both phos-
phorylated and non-phosphorylated STAT3. Leptin caused
increased STAT3 phosphorylation at 62 nM and 1 mM concentra-
tions as early as 5 min after stimulation and increases were
observed for at least 30 min (data not shown), consistent with
published reports in other leptin-responsive cell types39. Rapid
STAT3 phosphorylation suggests direct activation from the stimu-
lated LRb receptor. Based on these results, a leptin concentration of
100 nM was used for all subsequent experiments.
To quantify leptin-induced STAT3 phosphorylation, an extended
time course was performed [Fig. 2(C)]. Leptin induced STAT3 phos-
phorylation within 10 min and levels remained elevated 100 min
post-treatment. Densitometry indicated a 2.7- and 3.0-fold increase
in STAT3 stimulation at 10 and 30 min, respectively, following leptin
treatment. As controls, total proteinpools of STAT3 andGAPDHwere
determined and showed no signiﬁcant change between samples.
Similar results were observed in T/C-28a2 cells (data not shown).
Leptin induces STAT3 signaling and FZD1 expression in human
primary chondrocytes
To show that leptin effects were not speciﬁc to immortalized
chondrocyte cell lines, identical experiments were performed using
primary human chondrocytes [Fig. 3]. Treatment with 100 nM
leptin resulted in robust phosphorylation of STAT3 [Fig. 3(A)], while
Fig. 4. Leptin stimulation induces phosphorylation of STAT3 and expression of
FZD1 in osteoblasts.
Human fetal osteoblast cells (hFOB1.19) were treated with increasing concentrations of
leptin (0.62 to > 620 nM) and harvested over a time course (0e30 min or 0e48 h).
Whole cell lysates were separated by SDS-PAGE and analyzed using antibodies speciﬁc
for STAT3, phospho-STAT3, FZD1, FZD2 and FZD7. (A) Dose-dependent activation of
pSTAT3 was observed at both 15 and 30 min. (B) Leptin treatment (100 nM) resulted in
increased expression of FZD1, but no change in the levels of FZD2 and FZD7 expression.
Bands are shown as representative photographs from three or more separate experi-
ments. GAPDH protein levels analyzed as controls remained unchanged in all
experiments.
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Primary chondrocytes were treated with 100 nM leptin for 24 and
48 h prior to harvest and analyzed for expression of FZD1 and FZD7
[Fig. 3(B) and (C)]. Similar to the C-28/I2 cell line, signiﬁcant
increases in FZD1 and FZD7 protein levels were observed at 24 and
48 h after leptin treatment, while GAPDH remained unchanged.
FZD1 expression in chondrocytes is not regulated by IL-6
Leptin and IL-6, both members of the IL-6 cytokine superfamily,
activate closely related receptors. LRb and IL-6R have been shown
to activate similar JAK2, ERK1/2 and STAT3 signal transduction
pathways24,25. Furthermore, IL-6 is also secreted by adipose cells,
causes major effects on cells outside of the CNS and has been
implicated in several forms of arthritis. Therefore, as a control we
compared the function of IL-6 signaling with respect to regulation
of FZD1 expression in articular chondrocytes. To assess IL-6R
signaling, C-28/I2 cells were treated with IL-6 and cells were
harvested at various time points. We detected no increase in FZD1
expression at 6, 12, 24, or 48 h after IL-6 treatment
[Supplementary Fig. 1(A)]. Surprisingly, IL-6 stimulation of chon-
drocytes did not signiﬁcantly induce phosphorylation of JAK2,
ERK1/2, or STAT3 at all time points up to 100 min [Supplementary
Fig. 1(B)e(D)]. Total protein pools of JAK2, ERK1/2, STAT3 and
GAPDH remained unchanged in these studies. As a positive
control, IL-6 treatment of C-28/I2 cells resulted in a 2-fold increase
in the expression of BMPR-1A [Supplementary Fig. 1(E)], as
previously reported40. Collectively, our data suggest that LRb and
IL-6R act through distinct downstream signaling pathways in
articular chondrocytes. The results indicate that the observed
induction of FZD1 in articular chondrocytes is a speciﬁc effect of
leptin treatment.
Leptin induces STAT3 signaling and FZD1 expression in osteoblasts
OA is a complex disease that affects both chondrocytes and
osteoblasts in humans. To determine whether leptin affects
modulation of Wnt signaling in both chondrocytes and osteoblasts
through a conserved mechanism, we investigated whether leptin-
LRb-induced FZD1 expression was also operative in human osteo-
blasts. hFOB1.19 cells were treatedwith leptin (0.62 to>620 nM) for
15 and 30 min before cells were harvested and analyzed for STAT3
phosphorylation [Fig. 4(A)]. Similar to observations in chon-
drocytes, dose-responsive phosphorylation of STAT3 was observed
at both the 15 and 30-min time points, while the total protein pools
of STAT3 and GAPDH remained relatively unchanged. Additional
studies were then performed in hFOB1.19 cells to analyze FZD1,
FZD2 and FZD7 expression following leptin treatment. The hFOB1.19
cells were treated with 100 nM leptin for 0, 6, 12, 24, and 48 h prior
to harvest and analyzed. Similar to chondrocytes, signiﬁcant
increases in FZD1 protein levels were observed at 24 and 48 h after
leptin treatment. Interestingly, FZD7 and FZD2 protein levels
remained relatively unchanged [Fig. 4(B)], results similar to those
observed in the T/C-28a2 chondrocyte cell line. These data suggest
that leptin-LRb signaling-induced FZD1 expression may be opera-
tive in both articular chondrocytes and osteoblasts.
Leptin-induced JAK2-STAT3 phosphorylation and FZD1 expression
depends on LRb receptor stimulation
To test whether the leptin-activated LRb-JAK2 signaling
cascade was required for FZD1 induction, the JAK2 phosphoryla-
tion inhibitor AG490 was added to C-28/I2 cells 30 min prior to
leptin treatment. 48 h after leptin treatment, cells were harvested
and examined for FZD1 [Fig. 5(A)]. AG490 blocked leptin-stimulated expression of FZD1 induction, while GAPDH protein
levels were unaffected. These results suggest that the leptin-acti-
vated LRb-JAK2 signaling cascade is necessary for induced
expression of FZD1.
Once activated by the LRb receptor, phosphorylated JAK2
activates multiple downstream signaling pathways, including PI3K
[Fig. 6(A)]. To examine whether the JAK2-activated PI3K pathway
was required for FZD1 induction, PI3K inhibitors LY294002 and
wortmannin were added to C-28/I2 cells 30 min before leptin
treatment. 48 h after leptin treatment cells were harvested and
examined for FZD1 protein levels [Fig. 5(B) and (C)]. These results
showed that PI3K inhibitors had no effect on basal FZD1 levels or
leptin-induced FZD1 expression. As a control to show that leptin-
induced PI3K activity could be inhibited in these cells, we deter-
mined levels of phosphorylated Akt (a known downstream target
of JAK2-activated PI3K signaling) following leptin stimulation
[Fig. 6(D)]. Leptin stimulation of C-28/I2 cells resulted in a strong
increase in phosphorylated Akt 30 min after stimulation. Addition
of PI3K inhibitors LY294002 and wortmannin 30 min before leptin
treatment inhibited leptin-induced phosphorylation of Akt. Total
protein levels of both Akt and GAPDH showed little change with
addition of leptin or the inhibitors, suggesting that the LRb-JAK2-
PI3K pathway is not necessary for FZD1 induction.
To investigate the role of LRb-mediated JAK2-STAT phosphor-
ylation on induced FZD expression, we used an Epo-leptin
chimeric receptor (ELR), as articular chondrocytes do not express
the Epo receptor [Fig. 6(A)]. ELR is a fusion protein containing the
extracellular domain of the Epo receptor and an intracellular
domain of LRb. C-28/I2 cells were transfected in the presence or
absence of plasmid expressing wild-type ELR protein and sub-
jected to treatment with 10 mU/ml Epo. Cells were harvested
30 min after Epo treatment and analyzed for STAT3 phosphory-
lation [Fig. 6(B)]. There was no increase in STAT3 phosphorylation
upon Epo treatment in the absence of ELR, or with the expression
of ELR in the absence of Epo; however, there was a signiﬁcant
increase in STAT3 phosphorylation with Epo treatment in ELR
Fig. 6. LRb-mediated FZD1 expression is dependent on phosphorylation of tyro-
sine residues on LRb.
(A) Schematic representation of the hybrid receptor ELR consisting of the extracellular
domain of the Epo receptor and the intracellular domain of LRb. Indicated are JAK2,
JAK2-induced phosphorylated tyrosine residues (Tyr985, Tyr1077 and Tyr1138) and
respective downstream signaling pathways. C-28/I2 cells were transfected with ELR
expression plasmid (2 mg), treated with recombinant Epo (10 mU/ml) and harvested
over a time course (0e48 h). Whole cell lysates were analyzed using antibodies speciﬁc
for pSTAT3 (B) and FZD1 (C). Epo treatment of ELR transfectants induced phosphory-
lation of STAT3 (30 min) and increased expression of FZD1 at both 24 and 48 h. Bands
are shown as representative photographs from three or more separate experiments.
White lines separate nonadjacent lanes from the same gel. GAPDH protein levels
analyzed as controls remained unchanged during Epo treatment.
Fig. 5. Leptin-mediated FZD1 expression is dependent on LRb-JAK2 function but
not PI3K/Akt activity.
C-28/I2 cells were pre-treated with (A) the JAK2 inhibitor AG490 (50 nM), (B) the PI3K
inhibitor LY294002 (25 uM), and (C) the PI3K inhibitor wortmannin (50 nM) followed
by treatment with leptin (100 nM). Cells were harvested at 24 h and whole cell lysates
were separated by SDS-PAGE and analyzed using antibodies speciﬁc for FZD1. Leptin-
mediated increases in the expression of FZD1 were inhibited by pre-treatment with
AG490 but unchanged by pre-treatment with LY294002 or wortmannin. (D) Replicates
were harvested 30 min post-leptin treatment and analyzed using Akt and pAkt-speciﬁc
antibodies. Leptin-mediated activation of phospho-Akt was inhibited by pre-treatment
with either LY294002 or wortmannin. Bands are shown as representative photographs
from four or more separate experiments. White lines separate nonadjacent lanes from
the same gel. GAPDH protein levels analyzed as controls remained unchanged in all
experiments.
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throughout these experiments. We also used ELR transfectants to
determine whether leptin-induced FZD1 expression was due to
tyrosine phosphorylation of LRb. FZD1 protein levels remained
unchanged at 24 and 48 h with either Epo treatment alone or ELR
alone [Fig. 6(C)], and were signiﬁcantly higher only in the presence
of both ELR and Epo at both 24 and 48 h. GAPDH protein levels
remained unchanged between samples throughout the
experiments.
To test whether LRb-induced FZD1 expression is acting through
phosphorylation of speciﬁc tyrosine residues, ELR constructs con-
taining speciﬁc point mutations were used. ELR mutants included:
ELRL985, Tyr 985/leucine (Leu); ELRP1077, Tyr 1077/phenylalanine
(Phe); ELRS1138, Tyr 1138/serine (Ser) [Fig. 7(A)]. Following treat-
ment with Epo, increased phospho-STAT3 was observed in both
ELRL985 and ELRP1077 mutant transfectants but not in an ELRS1138
mutant transfectant [Fig. 7(A)]. Experiments were repeated and
analyzed for Epo-induced expression of FZD1 at 24 and 48 h. As
expected, Epo treatment of both ELRL985 and ELRP1077 transfectants
was associated with increased expression of FZD1, but no increase in
FZD1 expression was observed following Epo treatment of ELRS1138
transfectants [Fig. 7(B)]. In all mutant ELR transfection experiments,
GAPDH protein levels showed no signiﬁcant differences between
samples. These data indicate that in articular chondrocytes, the LRb-
JAK2-STAT3 signaling cascade functions through LRb Tyr1138, but
not Tyr985 or Tyr1077, and is required for leptin-mediated increases
in the expression of FZD1.Leptin modulates Wnt/b-catenin signaling in articular chondrocytes
To understand the functional consequence of leptin-LRb-induced
expression of FZD, we derived transduced C-28/I2 cells that harbor
a transgene consisting of three tandem Lef/TCF promoter elements
upstream of the cDNA for ﬁreﬂy luciferase. Activation of canonical
Wnt/b-catenin signaling via FZD/LRP5/6 receptor complexes in these
transduced cells induces dose-dependent luciferase expression.
Transduced C-28/I2 cells were treated with leptin alone (30 nM) for
24 h,Wnt3a alone (100 ng/ml) for 6 h, or sequentially with leptin for
24 h followed by Wnt3a for 6 h prior to harvest. Leptin treatment
alone showed no signiﬁcant increase in luciferase activity, while
Wnt3a alone showed an approximately 2.5-fold increase in relative
luciferase activity over untreated controls [Fig. 8]. Leptin treatment
prior to Wnt3a stimulation increased relative luciferase activity
approximately 6-fold. As a negative control, the soluble LRP6 inhib-
itor Dkk-1was added to replicates for each condition and completely
blocked Wnt3a-induced luciferase activity. These results show that
leptin-LRb signaling induces expression of FZD and in turn increases
responsiveness of the chondrocytes to Wnt/b-catenin signaling and
target gene expression.
Fig. 7. LRb-mediated FZD1 expression is Tyr1138-pSTAT3 dependent.
ELR variants containing substitutions of critical tyrosine residues (Tyr-Leu965, Tyr-Phe1077 and Tyr-Ser1138) were constructed into expression plasmids. Plasmids for ELRL985,
ELRP1077 and ELRS1138 (2 mg) were transfected separately into C-28/I2 cells. Cells were treated with recombinant Epo (10 mU/ml) and harvested at 30 min or 24 h, and whole cell
lysates were analyzed using antibodies speciﬁc for pSTAT3 and FZD1. (A) Epo-mediated ELR activation of pSTAT3 was unaffected in the ELRL985 and ELRP1077 transfectants but was
blocked in ELRS1138 transfectants. (B) Similarly, Epo-ELR-mediated increases in the expression of FZD1 were observed in ELRL985 and ELRP1077 transfectants but no increase in the
expression of FZD1 was observed in the ELRS1138 transfectants. Bands are shown as representative photographs from three or more separate experiments. White lines separate
nonadjacent lanes from the same gel. GAPDH protein levels analyzed as controls remained unchanged during Epo treatment.
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Leptin controls energy balance and body weight through leptin-
LRb signaling events that occur in speciﬁc CNS cells17,41e45.
Although several studies have shown that functional LRb is
expressed in both chondrocytes and osteoblasts, the physiological
role of peripheral leptin-LRb signaling in the adult musculoskeletal
system remains unknown39,46,47. Both acute and chronic exposure
to leptin have shown that leptin-LRb signaling events have signif-
icant effects on osteoblasts, including regulation of proliferation,
collagen synthesis, and bonemineralization; however, it is not clear
whether these leptin effects are direct or indirect23,47.
Studies in murine models of chondrocytes isolated from regions
of endochondral ossiﬁcation have shown that leptin-LRb signaling
is associated with increases in proliferation rates, insulin-like
growth factor-1 receptor abundance and type X collagen expres-
sion48,49. Leptin treatment also suppressed induction of apoptosis
in the murine endochondral chondrocytes48. Similarly, leptin
treatment of rabbit growth plate chondrocytes increased rates of
proliferation and proteoglycan expression50.
Although several investigators have shown that primary
human articular chondrocytes express functional LRb, the
physiological consequences of leptin-LRb signaling events in
differentiated articular chondrocytes remain to be deter-
mined8,51,52. The study of Simopoulou and colleagues showed
that long-term continuous exposure (5e7 days) of primary
human chondrocytes to leptin led to increases in amounts of
IL-1b, MMP-9 and MMP-13 proteins in treated cells52. However,
these changes in protein levels were not directly tied to speciﬁcLRb signaling events and did not exclude the activation of other
cell signaling pathways.
In this study we have shown that leptin-LRb signaling leads to
increases in the expression of FZD1 and FZD7 in both human
articular chondrocytes and osteoblasts. FZDs are seven-pass
transmembrane proteins that act as receptors for their cognate
glycoprotein ligands known as Wnts35. Binding of Wnts to FZD
receptors leads to signaling events that activate both canonical
and non-canonical downstream pathways. Canonical Wnt
signaling leads to inhibition of b-catenin degradation, its accu-
mulation and nuclear translocation. Nuclear b-catenin interacts
with transcription factors such as lymphoid enhancer-binding
factor-1/T cell-speciﬁc transcription factor to affect transcription of
speciﬁc Wnt target genes. The canonical Wnt/b-catenin signaling
pathway plays a central role in a variety of developmental
processes including primary musculoskeletal morphogenesis, cell
differentiation and proliferation, and tissue remodeling53. Wnt
signaling has been shown to regulate multiple physiological
pathways in both osteoblasts and chondrocytes to elicit matrix
catabolism54e59.
The effects of canonical Wnt/b-catenin signaling pathways in
differentiated articular chondrocytes in adult animals are less clearly
deﬁned. However, some evidence suggests that Wnt-b-catenin acti-
vation may regulate expression of enzymes involved in degradation
of extracellular matrix. Several reports have linked canonical Wnt/b-
catenin signaling to transcriptional regulation of cyclo-oxygenase-2
expression in cancer cells, and another study has associated Lef1with
regulation of cyclo-oxygenase-2 expression in chondrocytes27,60e62.
Activation of b-catenin in maturing chondrocytes is associated with
Fig. 8. Leptin modulates Wnt/b-catenin signaling in articular chondrocytes.
C-28/I2 cells were transduced with a recombinant lentivirus that contains three
tandem Lef/TCF promoter elements upstream of the cDNA for ﬁreﬂy luciferase. Acti-
vation of canonical Wnt/b-catenin signaling induces luciferase expression in the
transduced cells. Parallel aliquots of transduced cells were treated with recombinant
human leptin (30 nM), recombinant human Wnt3a (100 ng/ml), or sequentially with
leptin followed by Wnt3a. Recombinant human Dkk-1 (100 ng/ml) was added to
replicates as a soluble Wnt antagonist. Whole cell lysates were assayed in triplicate for
luciferase activity and the results expressed as RLU normalized to mg of total protein
content. Leptin treatment did not signiﬁcantly increase luciferase activity. Wnt3a
treatment increased luciferase activity (approximately 2.5-fold over controls) and
leptin plus Wnt3a treatment signiﬁcantly increased activity compared to controls,
leptin and Wnt3a treatment (approximately 6-fold over controls). In every case
increases in luciferase activity were inhibited by treatment with Dkk-1. Columns
indicate mean values with 95% conﬁdence intervals determined from at least ﬁve
separate experiments. Statistical signiﬁcance was evaluated by Student’s t-test. In
comparing Wnt3a treatment to the control (Wnt3a vs Control), P¼ 0.01; Wnt3a vs
Leptin, P¼ 0.021; Wnt3a vs Wnt3aþDkk-1, P¼ 0.008; LeptinþWnt3a vs Control,
P¼ 0.004; LeptinþWnt3a vs Leptin, P¼ 0.005; LeptinþWnt3a vs Wnt3a, P¼ 0.017; and
LeptinþWnt3a vs LeptinþWnt3aþDkk-1, P¼ 0.001.
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and MMP-1354. Other studies performed in cancer cells have shown
that canonical Wnt-b-catenin signaling can regulate the expression
of MMP-9 and MMP-1363,64. Both dysregulated expression of MMPs
and cyclo-oxygenase-2 have been implicated in the pathophysiology
of OA65,66.
Our data showed that leptin treatment of human chondrocytes
and osteoblasts induced de novo expression of FZD1 and FZD7 in
both a time- and dose-dependent manner [Fig. 1 and Fig. 4].
Signiﬁcant increases in the expression of FZD1 and FZD7 protein
occurred within 24 h following treatment with leptin. In addition,
we have shown that leptin-mediated increases in FZD1 protein
expression are not dependent on LRb-PI3K-Akt signaling but rather
are LRb-JAK2-STAT3 signaling dependent. FZD receptors have been
categorized into sub-families based on amino acid sequence and
structure. Human FZD1, FZD2, and FZD7 share a common structure
consisting of seven transmembrane domains, a cysteine-rich
domain in the N-terminal extracellular region, and the C-terminal
Ser/Thr-Xxx-Val motif, and share a high percentage of shared
primary amino acid sequences (>75%)67. Interestingly, in our
experiments, FZD2 expression was not increased in either chon-
drocytes or osteoblasts following leptin treatment. This observation
suggests that transcriptional regulation of speciﬁc FZD family
members likely includes cell type-speciﬁc factors that have yet to
be identiﬁed.
Our data supports the hypothesis that leptin-LRb signaling
regulates the expression of Wnt/b-catenin signaling pathway
components in chondrocytes and osteoblasts and allows for direct
cross-talk to occur between these two important signaling path-
ways. Additional investigation into the co-regulation of these
important signaling pathways in chondrocytes and osteoblasts may
provide insight into the pathophysiological changes that lead to the
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